Hodges Alan, Dubuque Rachel, Chen Shu-Hsia, Pan Ping-Ying
Center for Immunotherapy, Neal Cancer Center, Houston Methodist Research Institute, Houston, TX, 77030, USA.
Texas A&M University College of Medicine, Bryan, TX, 77807, USA.
Biomark Res. 2024 Dec 19;12(1):159. doi: 10.1186/s40364-024-00705-7.
The leukocyte immunoglobulin-like receptor B (LILRB) proteins, characterized by their transmembrane nature and canonical immunoreceptor tyrosine-based inhibitory motifs (ITIM) signaling, play a pivotal role in maintaining immune homeostasis and are implicated in the pathogenesis of various disease states. This comprehensive review will focus on the intricate involvement of the LILRB family in hematologic malignancies. These receptors have emerged as valuable diagnostic and prognostic biomarkers in leukemia, lymphoma, and myeloma. Beyond their prognostic implications, LILRBs actively shape the immune microenvironment and directly influence the disease pathogenesis of hematologic malignancies. Furthermore, their identification as potential therapeutic targets offer a promising avenue for precision medicine strategies in the treatment of these disorders. Currently, multiple LILRB directed therapies are in the preclinical and clinical trial pipelines. This review underscores the multifaceted role of the LILRB family in hematologic malignancies, highlighting their significance from diagnostic and prognostic perspectives to their broader impact on disease pathophysiology and as valuable therapeutic targets.
白细胞免疫球蛋白样受体B（LILRB）蛋白具有跨膜特性和典型的基于免疫受体酪氨酸的抑制性基序（ITIM）信号传导，在维持免疫稳态中起关键作用，并与多种疾病状态的发病机制有关。这篇综述将聚焦于LILRB家族在血液系统恶性肿瘤中的复杂作用。这些受体已成为白血病、淋巴瘤和骨髓瘤中有价值的诊断和预后生物标志物。除了其预后意义外，LILRB还积极塑造免疫微环境，并直接影响血液系统恶性肿瘤的疾病发病机制。此外，它们被确定为潜在的治疗靶点，为这些疾病的精准医学策略提供了一条有前景的途径。目前，多种针对LILRB的疗法正处于临床前和临床试验阶段。这篇综述强调了LILRB家族在血液系统恶性肿瘤中的多方面作用，突出了它们从诊断和预后角度到对疾病病理生理学的更广泛影响以及作为有价值的治疗靶点的重要性。
